Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Key Points

• Wall Street’s consensus rating is “Moderate Buy”: Of 14 analysts, 10 rate KRYS a buy, two a strong buy, one a hold and one a sell. The average 12-month price target is $375.
• Krystal Biotech’s latest quarter beat expectations, reporting EPS of $2.05 versus the $1.79 consensus and revenue of $127.34 million versus estimates of $125.77 million.
• Insiders sold shares in two disclosed transactions, while institutional investors and hedge funds own 86.29% of the stock.

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) has been given an average rating of "Moderate Buy" by the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $375.00.

Several equities research analysts recently issued reports on KRYS shares. Bank of America lifted their price objective on Krystal Biotech from $392.00 to $400.00 and gave the company a "buy" rating in a research note on Monday, September 21st. Weiss Ratings raised shares of Krystal Biotech from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, October 23rd. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research report on Wednesday, September 23rd. HC Wainwright reaffirmed a "buy" rating and set a $361.00 target price on shares of Krystal Biotech in a research report on Thursday, October 15th. Finally, Royal Bank Of Canada dropped their target price on shares of Krystal Biotech from $400.00 to $375.00 and set an "outperform" rating on the stock in a report on Tuesday.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares of the company's stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the business's stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares of the company's stock, valued at approximately $16,456,000. The trade was a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.10% of the stock is owned by company insiders.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Krystal Biotech during the 2nd quarter worth approximately $1,554,113,000. William Blair Investment Management LLC bought a new stake in shares of Krystal Biotech during the second quarter worth about $211,909,000. First Trust Advisors LP grew its holdings in Krystal Biotech by 42.9% during the first quarter. First Trust Advisors LP now owns 350,521 shares of the company's stock valued at $90,547,000 after purchasing an additional 105,245 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Krystal Biotech by 21.5% in the 1st quarter. Janus Henderson Group PLC now owns 266,659 shares of the company's stock worth $68,879,000 after buying an additional 47,219 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Krystal Biotech by 36.6% during the 1st quarter. Bank of America Corp DE now owns 260,647 shares of the company's stock valued at $67,330,000 after purchasing an additional 69,840 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $300.88 on Friday. The stock has a market cap of $8.91 billion, a P/E ratio of 40.83 and a beta of 0.56. The firm has a 50-day moving average of $332.48 and a two-hundred day moving average of $309.12. Krystal Biotech has a 1-year low of $192.52 and a 1-year high of $382.54.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.79 by $0.26. Krystal Biotech had a return on equity of 17.02% and a net margin of 47.91%. The firm had revenue of $127.34 million during the quarter, compared to analysts' expectations of $125.77 million. As a group, equities analysts expect that Krystal Biotech will post 7.74 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.